Overview

Safety Evaluation of Adverse Reactions in Diabetes

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of incretin-based antidiabetic therapies (DPP-4 inhibitors and GLP-1 agonists) on cardiovascular, gastrointestinal and renal system and to detail the mechanisms underlying their action in these systems.
Phase:
Phase 4
Details
Lead Sponsor:
Charles University, Czech Republic
Treatments:
Exenatide
Gliclazide
Linagliptin